• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管紧张素转换酶2(ACE2):严重急性呼吸综合征冠状病毒2(SARS-CoV-2)受体和肾素-血管紧张素系统(RAS)调节剂

Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator.

作者信息

Bian Jingwei, Li Zijian

机构信息

Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education; Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100191, China.

Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.

出版信息

Acta Pharm Sin B. 2021 Jan;11(1):1-12. doi: 10.1016/j.apsb.2020.10.006. Epub 2020 Oct 13.

DOI:10.1016/j.apsb.2020.10.006
PMID:33072500
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7553008/
Abstract

The coronavirus disease 2019 (COVID-19) outbreak is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Angiotensin-converting enzyme 2 (ACE2) was rapidly identified as the critical functional receptor for SARS-CoV-2. ACE2 is well-known as a counter-regulator of the renin-angiotensin system (RAS) and plays a key role in the cardiovascular system. Given that ACE2 functions as both a SARS-CoV-2 receptor and a RAS modulator, the treatment for COVID-19 presents a dilemma of how to limit virus entry but protect ACE2 physiological functions. Thus, an in-depth summary of the recent progress of ACE2 research and its relationship to the virus is urgently needed to provide possible solution to the dilemma. Here, we summarize the complexity and interplay between the coronavirus, ACE2 and RAS (including anti-RAS drugs). We propose five novel working modes for functional receptor for SARS-CoV-2 infection and the routes of ACE2-mediated virus entering host cells, as well as its regulatory mechanism. For the controversy of anti-RAS drugs application, we also give theoretical analysis and discussed for drug application. These will contribute to a deeper understanding of the complex mechanisms of underlying the relationship between the virus and ACE2, and provide guidance for virus intervention strategies.

摘要

2019冠状病毒病(COVID-19)疫情由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起。血管紧张素转换酶2(ACE2)很快被确定为SARS-CoV-2的关键功能受体。ACE2作为肾素-血管紧张素系统(RAS)的一种反调节因子广为人知,在心血管系统中起关键作用。鉴于ACE2既作为SARS-CoV-2受体又作为RAS调节剂发挥作用,COVID-19的治疗面临着如何限制病毒进入但又保护ACE2生理功能的两难境地。因此,迫切需要深入总结ACE2研究的最新进展及其与该病毒的关系,以提供解决这一两难困境的可能方案。在此,我们总结了冠状病毒、ACE2和RAS(包括抗RAS药物)之间的复杂性和相互作用。我们提出了SARS-CoV-2感染功能性受体的五种新工作模式、ACE2介导病毒进入宿主细胞的途径及其调控机制。对于抗RAS药物应用的争议,我们也进行了理论分析并讨论了药物应用问题。这些将有助于更深入地理解病毒与ACE2之间关系的复杂机制,并为病毒干预策略提供指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/4b8a1eccde48/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/b628f5e1ca0c/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/041c4dcd8252/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/a6d4ade2329e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/d6802269c006/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/5b265557a706/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/6f9e1a161d30/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/9fc5199e112b/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/4b8a1eccde48/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/b628f5e1ca0c/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/041c4dcd8252/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/a6d4ade2329e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/d6802269c006/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/5b265557a706/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/6f9e1a161d30/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/9fc5199e112b/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4459/7838025/4b8a1eccde48/gr7.jpg

相似文献

1
Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator.血管紧张素转换酶2(ACE2):严重急性呼吸综合征冠状病毒2(SARS-CoV-2)受体和肾素-血管紧张素系统(RAS)调节剂
Acta Pharm Sin B. 2021 Jan;11(1):1-12. doi: 10.1016/j.apsb.2020.10.006. Epub 2020 Oct 13.
2
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
3
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).血管紧张素转化酶 2(ACE2)、严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)与 2019 冠状病毒病(COVID-19)的病理生理学。
J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10.
4
Insights on SARS-CoV-2 Molecular Interactions With the Renin-Angiotensin System.关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与肾素-血管紧张素系统分子相互作用的见解
Front Cell Dev Biol. 2020 Sep 16;8:559841. doi: 10.3389/fcell.2020.559841. eCollection 2020.
5
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.SARS-CoV-2 利用血管紧张素转换酶 2 进入细胞进行复制的机制概述:与肾素-血管紧张素系统相关的可能治疗选择。
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):317-325. doi: 10.1093/ehjcvp/pvaa053.
6
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.下调膜结合血管紧张素转换酶 2(ACE2)受体在 COVID-19 免疫病理中起关键作用。
Curr Drug Targets. 2021;22(3):254-281. doi: 10.2174/1389450121666201020154033.
7
Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.新型冠状病毒相关肺损伤中经典肾素-血管紧张素系统与其拮抗系统之间的失衡。
Am J Physiol Lung Cell Mol Physiol. 2020 Aug 1;319(2):L325-L336. doi: 10.1152/ajplung.00189.2020. Epub 2020 Jul 8.
8
The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.血管紧张素转换酶2(ACE2)在新型冠状病毒肺炎及基础合并症治疗中的双向开关作用
Molecules. 2020 Dec 31;26(1):142. doi: 10.3390/molecules26010142.
9
Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.呼吸系统疾病背景下的血管紧张素转换酶2(ACE2)及其在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染中的重要性
Pharmaceuticals (Basel). 2021 Aug 17;14(8):805. doi: 10.3390/ph14080805.
10
Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.多功能血管紧张素转换酶 2,SARS-CoV-2 进入受体,以及对其在急性肺损伤中作用的批判性评价。
Biomed Pharmacother. 2021 Apr;136:111193. doi: 10.1016/j.biopha.2020.111193. Epub 2021 Jan 5.

引用本文的文献

1
The Renin-Angiotensin System Modulates SARS-CoV-2 Entry via ACE2 Receptor.肾素-血管紧张素系统通过ACE2受体调节新型冠状病毒2型(SARS-CoV-2)的进入。
Viruses. 2025 Jul 19;17(7):1014. doi: 10.3390/v17071014.
2
Structural and Energetic Insights into SARS-CoV-2 Evolution: Analysis of hACE2-RBD Binding in Wild-Type, Delta, and Omicron Subvariants.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进化的结构与能量学见解:野生型、德尔塔和奥密克戎亚变体中hACE2-RBD结合分析
Int J Mol Sci. 2025 Apr 17;26(8):3776. doi: 10.3390/ijms26083776.
3
The Effect of COVID-19 on Arterial Stiffness and Inflammation: A Longitudinal Prospective Study.

本文引用的文献

1
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.CD147-刺突蛋白是 SARS-CoV-2 感染宿主细胞的新途径。
Signal Transduct Target Ther. 2020 Dec 4;5(1):283. doi: 10.1038/s41392-020-00426-x.
2
Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.基于生理药代动力学模型的磷酸氯喹治疗新型冠状病毒肺炎的剂量选择
Acta Pharm Sin B. 2020 Jul;10(7):1216-1227. doi: 10.1016/j.apsb.2020.04.007. Epub 2020 Apr 20.
3
Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight.
2019冠状病毒病对动脉僵硬度和炎症的影响:一项纵向前瞻性研究。
Viruses. 2025 Mar 11;17(3):394. doi: 10.3390/v17030394.
4
Modulation of RAAS receptors and miRNAs in COVID-19: implications for disease severity, immune response, and potential therapeutic targets.新型冠状病毒肺炎中肾素-血管紧张素-醛固酮系统(RAAS)受体和微小RNA(miRNA)的调节:对疾病严重程度、免疫反应及潜在治疗靶点的影响
BMC Infect Dis. 2025 Mar 24;25(1):399. doi: 10.1186/s12879-025-10803-y.
5
Severe COVID-19 Pneumonia, Opportunistic Candida krusei Infection, and Acute Respiratory Distress Syndrome with Pulmonary Arterial Hypertension Treated with Bosentan: A Case Report.重症新型冠状病毒肺炎、克鲁斯念珠菌机会性感染以及合并肺动脉高压的急性呼吸窘迫综合征的波生坦治疗:一例报告
Am J Case Rep. 2025 Feb 24;26:e946400. doi: 10.12659/AJCR.946400.
6
Identification of Novel Genomic Variants in COVID-19 Patients Using Whole-Exome Sequencing: Exploring the Plausible Targets of Functional Genomics.使用全外显子组测序鉴定新冠病毒肺炎患者的新型基因组变异:探索功能基因组学的潜在靶点
Biochem Genet. 2024 Nov 18. doi: 10.1007/s10528-024-10970-8.
7
Sivelestat protects against acute lung injury by up-regulating angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptors.西维来司他通过上调血管紧张素转换酶2/血管紧张素-(1-7)/Mas受体来预防急性肺损伤。
J Thorac Dis. 2024 Sep 30;16(9):6182-6195. doi: 10.21037/jtd-24-1281. Epub 2024 Sep 26.
8
The Role of ACE2 in Neurological Disorders: From Underlying Mechanisms to the Neurological Impact of COVID-19.ACE2 在神经紊乱中的作用:从潜在机制到 COVID-19 对神经系统的影响。
Int J Mol Sci. 2024 Sep 15;25(18):9960. doi: 10.3390/ijms25189960.
9
ACE2 deficiency inhibits thoracic aortic dissection by enhancing SIRT3 mediated inhibition of inflammation and VSCMs phenotypic switch.ACE2 缺乏通过增强 SIRT3 介导的炎症抑制和 VSCMs 表型转换来抑制胸主动脉夹层。
Mol Med. 2024 Sep 19;30(1):154. doi: 10.1186/s10020-024-00926-4.
10
Perindopril decreases angiotensin-converting enzyme 2 (ACE2) expression in human adipocytes exposed to SARS-CoV-2 S1 spike protein.培哚普利降低暴露于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)S1刺突蛋白的人脂肪细胞中血管紧张素转换酶2(ACE2)的表达。
Narra J. 2024 Aug;4(2):e746. doi: 10.52225/narra.v4i2.746. Epub 2024 May 2.
高致病性冠状病毒:将疫苗研发置于聚光灯下。
Acta Pharm Sin B. 2020 Jul;10(7):1175-1191. doi: 10.1016/j.apsb.2020.05.009. Epub 2020 May 30.
4
AGTR2, One Possible Novel Key Gene for the Entry of SARS-CoV-2 Into Human Cells.血管紧张素 II 受体 2(AGTR2),新冠病毒进入人体细胞的一个可能的新关键基因。
IEEE/ACM Trans Comput Biol Bioinform. 2021 Jul-Aug;18(4):1230-1233. doi: 10.1109/TCBB.2020.3009099. Epub 2021 Aug 6.
5
Cell entry mechanisms of SARS-CoV-2.SARS-CoV-2 的细胞进入机制。
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734. doi: 10.1073/pnas.2003138117. Epub 2020 May 6.
6
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.SARS-CoV-2 刺突蛋白中的多碱性裂解位点对于感染人肺细胞至关重要。
Mol Cell. 2020 May 21;78(4):779-784.e5. doi: 10.1016/j.molcel.2020.04.022. Epub 2020 May 1.
7
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
8
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
9
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.使用临床级别的可溶性人血管紧张素转化酶 2 抑制工程化人类组织中的 SARS-CoV-2 感染。
Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.
10
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.CD147 作为 COVID-19 治疗靶点:阿奇霉素和干细胞干预的建议作用。
Stem Cell Rev Rep. 2020 Jun;16(3):434-440. doi: 10.1007/s12015-020-09976-7.